BIOVF (BIOVF) Stock Price & Analysis
BIOVF (BIOVF) fell 0.26% to USD 47.35 as of June 10, 2026 at 02:21 UTC, according to Nexqual real-time market data.
BIOVF last closed at USD 47.48; the session ranged USD 47.35–47.35 on volume of 200 shares. Market capitalization is $16.44B, with a 52-week range of USD 27.06–48 (PNK). Source: Nexqual, June 10, 2026 at 02:21 UTC.
Key Statistics (as of June 10, 2026 at 02:21 UTC)
| Price | USD 47.35 |
|---|---|
| Change | ▼ 0.26% (down) |
| Previous Close | USD 47.48 |
| Open | USD 47.35 |
| Day Range | USD 47.35 – 47.35 |
| 52-Week Range | USD 27.06 – 48 |
| Volume | 200 shares |
| Market Cap | $16.44B |
| Exchange | PNK |
Technical Analysis (BIOVF)
Nexqual's technical model rates BIOVF "BUY" based on 5 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 02:21 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 44.17) |
| MACD | 0.92 (positive) |
Analyst Ratings (BIOVF)
Wall Street analysts rate BIOVF "None", per Nexqual as of June 10, 2026 at 02:21 UTC.
| Consensus Rating | None |
|---|
Earnings (BIOVF)
| Next Earnings Date | 2026-07-16 |
|---|---|
| Revenue Estimate | $7.26B |
Source: Nexqual, June 10, 2026 at 02:21 UTC.
Financials & Fundamentals (BIOVF)
| Revenue Growth (YoY) | +11.10% |
|---|---|
| Gross Margin | +78.68% |
| Operating Margin | +0.00% |
| Profit Margin | +3.18% |
| ROE | +2.31% |
| Debt / Equity | 47.2 |
| Current Ratio | 0.71 |
| Free Cash Flow | $4.13B |
Source: Nexqual, June 10, 2026 at 02:21 UTC.
Financial Health Score (BIOVF)
Nexqual rates BIOVF's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:21 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 79%, operating 0% |
| Balance Sheet | Mixed — Debt/Equity 0.5x |
| Cash Flow | Solid — FCF $4.13B, 15% margin |
| Efficiency | Weak — ROE 2%, ROA 7.0% |
Ownership (BIOVF)
| Insider Ownership | +10.05% |
|---|---|
| Institutional Ownership | +74.35% |
| Shares Outstanding | 345.85M |
| Float | 221.93M |
Source: Nexqual, June 10, 2026 at 02:21 UTC.
Leadership (BIOVF)
BIOVF is led by Guido Oelkers (age 60), CEO & President, per Nexqual as of June 10, 2026 at 02:21 UTC.
| CEO & President | Guido Oelkers (age 60) |
|---|---|
| Chief Financial Officer | Henrik Stenqvist M.Sc. (age 58) |
Major Backers & Investors (BIOVF)
Notable institutional backers of BIOVF include Fidelity, Artisan Partners Funds Inc.-Artisan International Small-Mid Fund, Charles Schwab, according to Nexqual as of June 10, 2026 at 02:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.56% |
| Artisan Partners Funds Inc.-Artisan International Small-Mid Fund | 0.22% |
| Charles Schwab | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.77% |
| BlackRock | 0.68% |
Source: Nexqual, June 10, 2026 at 02:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IPSEY | Ipsen S.A. | USD 42.27 | ▼ 6.15% |
| HKMPF | Hikma Pharmaceuticals plc. | USD 19.07 | ▼ 1.14% |
| APNHY | Aspen Pharmacare Holdings plc | USD 9.03 | ▲ 1.8% |
| HKMPY | Hikma Pharmaceuticals plc. | USD 39.08 | ▼ 0.48% |
| SGIOY | Shionogi & Co. Ltd. | USD 8.56 | ▼ 2.28% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:21 UTC. This page is informational and not investment advice.